Skip to main content
. 2019 Feb 25;10:240. doi: 10.3389/fimmu.2019.00240

Figure 3.

Figure 3

PTX3 and CRP levels in aHUS acute phase and remission. PTX3 (A) and CRP (B) levels of aHUS patients are shown in the acute phase (black squares) and in remission (empty squares) with a continuous line connecting the respective sample pairs, while the medians of each group are indicated by a horizontal line. Half of the patients (N = 22, left) had a confirmed likely pathogenic mutation, 11 patients presented with anti-factor H antibodies (middle) and by the rest (N = 11, right) no likely pathogenic mutation has been identified in the complement genes (CFH, CFHR5, CFI, CD46, C3, CFB), THBD or DGKE. Data points represent mean of technical duplicates, statistical analysis was performed with the Wilcoxon-signed rank test, statistical significance is indicated by asterisks (**p < 0.01; ***p < 0.001). aHUS, atypical hemolytic uremic syndrome; CRP, C-reactive protein; PTX3, pentraxin-3.